[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639557":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":45,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cirrhotic patients treated by β-lactams",null,"Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by β-lactams",[13],"Drug: β-lactams",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","β-lactams","Participants receiving β-lactams were included.",[9],[21],{"name":22,"affiliation":5,"role":23},"Dayu Chen","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+862583106666","cdy_pharmacy@njglyy.com",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Nanjing","Jiangsu","210008","China","CN",{"type":38,"coordinates":39},"Point",[40,41],118.77778,32.06167,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"type":23,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chen Dayu","Pharmacist in Charge","100639557","clinical-efficacy-and-population-pharmacokinetics-of--lactams-in-cirrhotic-patients-100639557",false,"NCT07612163","Clinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients","Clinical Efficacy and Population Pharmacokinetics of β-lactams in Patients With Liver Cirrhosis: A Retro-prospective Observational Study","Inclusion Criteria:\n\nAge over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy\n\nExclusion Criteria:\n\nDuration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams","ALL","18 Years",{"count":58,"type":59},1000,"ESTIMATED","OBSERVATIONAL","Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.",[63],"Bacterial Infections",[65,63,66],"β-lactam","Liver cirrhosis","2026-05-21",{"date":69,"type":70},"2026-05-28","ACTUAL",{"date":72,"type":70},"2023-12-31",{"date":74,"type":59},"2027-12-31",{"name":5,"class":6},1]